Public Health
Coronavirus treatment update: Where we stand today
Our latest coronavirus treatment update highlights the options that appear to work, ones that might, and ones that failed to live up to their promise.
Inhaled coronavirus drug shows promise in small trial
An inhaled coronavirus drug containing interferon beta decreased patients’ chances of becoming severely ill by 79%, according to its creator.
Remote therapy is as effective as face-to-face, for depression
The pandemic has therapists' couches off limits. A new study finds that remote therapy may be as effective for depression as face-to-face, so I gave it a try.
Oxford COVID-19 vaccine triggers strong immune response
An Oxford COVID-19 vaccine triggered the creation of antibodies and T cells in trial participants, according to promising results published in The Lancet.
How to explain falling COVID-19 mortality rates
COVID-19 mortality rates are dropping in the U.S. and other nations — a few theories explain why more people are surviving the coronavirus.
"T cells" could provide immunity after antibodies fade
T cells that combat SARS-CoV-2 have been discovered in people who never had COVID-19, potentially putting natural herd immunity within our grasp.
Moderna’s COVID-19 vaccine produces more antibodies than infection
Two shots of Moderna’s COVID-19 vaccine produces more antibodies than a coronavirus infection, according to Phase 1 preliminary data.
Study: Risk of death from COVID-19 is 45% lower on arthritis drug
The arthritis drug tocilizumab may lower ventilated patients' risk of death from COVID-19 by 45%, according to a retrospective study.
Survivors’ plasma might prevent coronavirus infections
Injections of COVID-19 survivors' blood plasma might prevent coronavirus infections, making them a promising stopgap until a vaccine is ready.
FDA: Smokeless cigarettes produce less harmful chemicals
FDA clears Philip Morris to market its smokeless cigarettes as modified risk tobacco products, which could benefit smokers battling a nicotine addiction.